Key points from article :
British startup Sava has raised $19 million in Series A funding to advance its wearable biosensor technology. The company, founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, has developed a microsensor that detects multiple biomarkers beneath the skin in real time.
The first product, a next-generation continuous glucose monitor (CGM), was tested in a clinical trial with 50 diabetes patients at Oxford and Cambridge. The device provided accurate glucose readings for up to 10 days, a significant improvement over current filament-based sensors that are often uncomfortable and short-lived.
Sava’s technology streams molecular data directly to a smartphone, aiming to make monitoring more accessible and less invasive. Michali said the results show the system could match current top CGMs while avoiding their cost and discomfort.
The platform is modular, meaning it could eventually track other molecules such as lactate, amino acids, or ketone bodies. Circi explained that the vision is real-time personalized healthcare, where people can monitor many aspects of their health through one device.
The funding round, which brings Sava’s total to $32 million, was led by Balderton Capital and Pentland Ventures, with several other investors. The money will support scaling the team, manufacturing, and regulatory approvals.
